Navigation Links
Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
Date:6/16/2013

creased appetite (21%) and were consistent with previously reported data. Only 7% of patients discontinued due to an AE.

"The results of this single-agent study are encouraging. It is exciting to see how active ibrutinib is in the treatment of relapsed and refractory mantle cell lymphoma, particularly as the responses appear to last.," said Professor Simon Rule, Consultant Haematologist in the Department of Haematology at the Derriford Hospital in Plymouth, United Kingdom. "What is equally important is that no new safety signals were observed during this study."

The MCL study was a Phase 2 multicenter, open-label, study including 111 patients with relapsed/refractory MCL at 18 sites internationally. Patients had received a median of three prior therapies and were enrolled into two cohorts based on prior bortezomib exposure – either bortezomib-naive (n=63) or bortezomib-exposed (n=48), with both groups receiving 560 mg of ibrutinib orally, once a day. The primary endpoint of the study was ORR. Secondary endpoints included DOR, PFS, OS and frequency and severity of adverse events.

Ibrutinib in Relapsed/Refractory DLBCL
In the second Phase 2 study involving patients with relapsed/refractory DLBCL (n=70), investigators tested the hypothesis that ibrutinib would be more active in the Activated B-cell-like (ABC) subtype compared to the Germinal Center B-cell-like (GCB) subtype, given that the ABC subtype is dependent on the B-cell antigen receptor (BCR) pathway. Ibrutinib targets the BCR pathway by inhibiting BTK, a critical mediator in malignant B-cell growth and proliferation. Results of the study show that:

  • Patients with the ABC subtype showed a significantly greater response to ibrutinib monotherapy compared to those with the GCB subtype (ORR = 41% vs 5%, p=0.007, Fisher's exact test).
  • Median OS was 9.76 months for
    '/>"/>

SOURCE Janssen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
5. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
8. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... BURLINGAME, Calif. , July 30, 2015 /PRNewswire/ ... Patent and Trademark Office has granted the company ... property covering Cleave,s lead molecule CB-5083. ... quinazolines as inhibitors of p97," U.S. 9,062,026, allows ... CB-5083, a first-in-class, highly selective oral inhibitor of ...
(Date:7/30/2015)... CHICAGO , July 30, 2015 Flexpoint ... and financial services sectors, today announced that it has ... and Bryan Stuart to form Kastle Therapeutics, ... Chicago , will focus on acquiring, developing and ... needs. Target acquisition opportunities include select therapies already approved ...
(Date:7/30/2015)... July 30, 2015  Cardinal Health today reported ... an increase of 20 percent, and non-GAAP diluted ... $1.00, an increase of 20 percent. Non-GAAP operating ... a GAAP basis, operating earnings increased 44 percent ... operations increased 29 percent to $0.88. ...
Breaking Medicine Technology:Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 3Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 2Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 3Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 4Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 5Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 6Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 7Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 8Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 9Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 10Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 11Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 12Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 13Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 14Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 15Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 16Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 17Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 18Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 19Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 20Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 21Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 22Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 23Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 24Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 25Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 26Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 27Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 28Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 29Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 30Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 31Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 32Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 33Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 34
... StreamVenue Healthcare has partnered its "plug and play" ... Medicine to teach, and to better manage post-surgical patient ... surgeons and physical therapists to view cases and discuss ... cohesive communication and creates a live classroom for teaching ...
... Reportlinker.com announces that a new market research ... Middle East and Africa ENT Devices Market ... Middle East and Africa ENT ... Summary GlobalData,s new report, "Middle ...
Cached Medicine Technology:StreamVenue Healthcare Connects Endoscopy Technology With Athletic Trainers 2Reportlinker Adds Middle East and Africa ENT Devices Market Outlook to 2017 2
(Date:7/30/2015)... ... July 30, 2015 , ... " ... which takes a look at small, medium, and large businesses making an impact ... conducted the business review and shared with viewers how DevExpress has provided software ...
(Date:7/30/2015)... ... 30, 2015 , ... The need for accessibility is never greater than when ... patients as well as visiting friends and family during these critical moments, hospitals around ... stations - powered by ChargeItSpot , a Philadelphia-based startup that recently secured a ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... New Tool That Increases Training Capability , World renown body weight ... Zejax ( http://www.Zejax.com ), that dramatically increases a person’s training capability. , The ...
(Date:7/30/2015)... ... 30, 2015 , ... Western University of Health Sciences faculty, students and alumni ... the largest sports and humanitarian event in the world this year and the single ... held July 25 through August 2, 2015, benefited from the participation of WesternU’s colleges ...
(Date:7/30/2015)... ... 30, 2015 , ... Quintessa Medical Spa is happy to offer patients the ... designed specifically for the elimination of excess tissue under the chin, referred to as ... of Wisconsin to offer this innovative treatment. , Developed by Kythera Biopharmaceuticals, Kybella was ...
Breaking Medicine News(10 mins):Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2
... Cart Allows Easier Operation and Improved Workflow for ... Inc., the pioneer and world leader in image ... designed system cart for the PercuNav interventional imaging ... # 322 of the Society of Interventional Radiology,s ...
... LCA-Vision Inc. (Nasdaq: LCAV ), a leading ... (R) brand, today announced that members of its executive management ... Investors Conference on Monday, March 9, 2009 at 8:40 a.m. ... JW Marriott Grande Lakes Hotel in Orlando, Fla. A ...
... LONDON, March 2 Providing low-cost, yet high quality ... will need to address in order to succeed in ... The cost of after-sales service will also prove to ... Certain segments, including operating room monitors and critical care ...
... Corporation (Nasdaq: CSCX ), a global leader ... announced today that it will release its fourth quarter ... the market close. The Company has scheduled a conference ... Time. During the call, Cardiac Science management will ...
... 2 Misys plc (LSE:MSY), the global,application software and services ... required to gain the SWIFTReady Trade Services,Utility (TSU) 2009 label. ... provider to be awarded this when the,SWIFTNet TSU service came ... which was then accredited again in 2008. , ...
... to be at the forefront of the "Eco Friendly and Green" ... website, BuyEcoAwards.com. The focus of this website is to promote environmentally ... ... Placentia, CA (PRWEB) March 2, 2009 -- Striving to ...
Cached Medicine News:Health News:Traxtal to Introduce Next-Generation PercuNav System Cart at SIR Annual Scientific Meeting 2Health News:Frost & Sullivan Says, Rising Awareness Boosts High Acuity Areas Monitoring Systems Market in Eastern Europe 2Health News:Frost & Sullivan Says, Rising Awareness Boosts High Acuity Areas Monitoring Systems Market in Eastern Europe 3Health News:Frost & Sullivan Says, Rising Awareness Boosts High Acuity Areas Monitoring Systems Market in Eastern Europe 4Health News:Cardiac Science Schedules Fourth Quarter Earnings Release and Announces Conference Call 2Health News:Misys Wins SWIFTReady TSU 2009 Accreditation for Third Year Running 2Health News:Misys Wins SWIFTReady TSU 2009 Accreditation for Third Year Running 3Health News:Allstar Awards Announces its New Ecologically Friendly Product Website 2Health News:Allstar Awards Announces its New Ecologically Friendly Product Website 3
The care package includes a spare motor, fuse, Spare Fluorescent Bulb, additional Vibratome Feather Blades, Specimen Adhesive, Specimen Mounting Blocks, and a Specimen Tray....
... several (10 to 12) brain slices to ... while maintaining excellent viability. A mixture of ... saline. This initiates a circular flow and ... slices. Slices remain viable for hours while ...
... cooling water for the Vibratome 900R when it is ... in a location which has no source of tap ... thermoelectric heat pump. The reservoir tank holds seven ... 900R for up to eight hours. Water is ...
Punch set for Advanced Tissue Arrayer, 0.6 mm...
Medicine Products: